Not to be confused with quinine or quifenadine.
Quinidine
|
| Clinical data |
| Trade names |
Quinaglute, Quinidex |
| AHFS/Drugs.com |
Monograph |
Pregnancy
category |
- AU: C
- US: C (Risk not ruled out)
|
Routes of
administration |
Oral, IM, IV |
| ATC code |
|
| Legal status |
| Legal status |
- AU: S4 (Prescription only)
- CA: ℞-only
- UK: POM (Prescription only)
- US: ℞-only
|
| Pharmacokinetic data |
| Bioavailability |
70–85% |
| Metabolism |
50–90% (by liver) |
| Biological half-life |
6–8 hours |
| Excretion |
by the liver (20% as unchanged quinidine via urine) |
| Identifiers |
IUPAC name
- (S)-(6-Methoxyquinolin-4-yl)[(1S,2R,4S,5R)-5-vinylquinuclidin-2-yl]methanol
|
| Synonyms |
(2-Ethenyl-4-azabicyclo[2.2.2]oct-5-yl)-(6-methoxyquinolin-4-yl)-methanol |
| CAS Number |
|
| PubChem CID |
|
| IUPHAR/BPS |
|
| DrugBank |
|
| ChemSpider |
|
| UNII |
|
| KEGG |
|
| ChEBI |
|
| ChEMBL |
|
| ECHA InfoCard |
100.000.254 |
| Chemical and physical data |
| Formula |
C20H24N2O2 |
| Molar mass |
324.417 g/mol |
| 3D model (Jmol) |
|
SMILES
-
O(c4cc1c(nccc1[C@H](O)[C@@H]2N3CC[C@@H](C2)[C@@H](/C=C)C3)cc4)C
|
InChI
-
InChI=1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14-,19+,20-/m0/s1 Y
-
Key:LOUPRKONTZGTKE-LHHVKLHASA-N Y
|
| NY (what is this?) (verify) |
Quinidine is a pharmaceutical agent that acts as a class I antiarrhythmic agent (Ia) in the heart. It is a stereoisomer of quinine, originally derived from the bark of the cinchona tree. The drug causes increased action potential duration, as well as a prolonged QT interval.
Contents
- 1 Mechanism
- 2 History
- 3 Elimination
- 4 Side effects
- 5 Other uses
- 6 Veterinary Usage
- 7 See also
- 8 References
- 9 External links
Mechanism
Like all other class I antiarrhythmic agents, quinidine primarily works by blocking the fast inward sodium current (INa). Quinidine's effect on INa is known as a 'use dependent block'. This means at higher heart rates, the block increases, while at lower heart rates, the block decreases. The effect of blocking the fast inward sodium current causes the phase 0 depolarization of the cardiac action potential to decrease (decreased Vmax).
Quinidine also blocks the slowly inactivating, tetrodotoxin-sensitive Na current, the slow inward calcium current (ICa), the rapid (IKr) and slow (IKs) components of the delayed potassium rectifier current, the inward potassium rectifier current (IKI), the ATP-sensitive potassium channel (IKATP) and Ito.
At micromolar concentrations, quinidine inhibits Na+/K+-ATPase by binding to the same receptor sites as the digitalis glycosides such as ouabain.
The effect of quinidine on the ion channels is to prolong the cardiac action potential, thereby prolonging the QT interval on the surface ECG.
Other ECG effects include a wide notched P wave, wide QRS complex, depressed ST segment, and U waves. These are the results of both slowed depolarization and repolarization.
History
The effects of cinchona bark (the botanical source from which quinidine is extracted) had been commented on long before the understanding of cardiac physiology arose. Jean-Baptiste de Sénac, in his 1749 work on the anatomy, function, and diseases of the heart, had this to say,
"Long and rebellious palpitations have ceded to this febrifuge".[1]
"Of all the stomachic remedies, the one whose effects have appeared to me the most constant and the most prompt in many cases is quinquina [Peruvian bark] mixed with a little rhubarb."[2]
Sénac subsequently became physician to Louis XV of France, a counselor of the state, and superintendent of the mineral waters and medicinals in France. As a result of his influence, throughout the 19th century, quinine was used to augment digitalis therapy. It was described as das Opium des Herzens (the opium of the heart).
However, the use of quinidine to treat arrhythmia really only came into its own because a physician listened to the astute observation of one of his patients. In 1912, Karel Frederik Wenckebach saw a man with atrial fibrillation. He was a Dutch merchant, used to good order in his affairs. He would like to have good order in his heart business, also, and asked, "why there were heart specialists if they could not abolish this very disagreeable phenomenon ... he knew himself how to get rid of his attacks. As I did not believe him, he promised to come back next morning with a regular pulse, and he did."
The man had found by chance that when he took one gram of quinine during an attack, it reliably halted it in 25 minutes; otherwise it would last for two to 14 days. Wenckebach often tried quinine again, but he succeeded in only one other patient.[1]
He made passing mention of it in his book on cardiac arrhythmias published in 1914. Four years later, Walter von Frey of Berlin reported in a leading Viennese medical journal that quinidine was the most effective of the four principal cinchona alkaloids in controlling atrial arrhythmias.[3]
Elimination
The half life of oral quinidine is six to eight hours, and it is eliminated by the cytochrome P450 system in the liver. About 20% is excreted unchanged via the kidneys.
Side effects
Quinidine is also an inhibitor of the cytochrome P450 enzyme 2D6, and can lead to increased blood levels of lidocaine, beta blockers, opioids, and some antidepressants. Quinidine also inhibits the transport protein P-glycoprotein and so can cause some peripherally acting drugs such as loperamide to have central nervous system side effects, such as respiratory depression, if the two drugs are coadministered.[4]
Quinidine can cause thrombocytopenia, granulomatous hepatitis, myasthenia gravis, and torsades de pointes, so is not used much today. Torsades can occur after the first dose. Quinidine-induced thrombocytopenia (low platelet count) is mediated by the immune system, and may lead to thrombocytic purpura.
Quinidine intoxication can lead to a collection of symptoms collectively known as cinchonism, with tinnitus (ringing in the ears) being among the most characteristic and common symptoms of this toxicity syndrome. Quinidine toxicity can also invoke episodes of Torsades de Pointes - a rapid and dangerous ventricular rhythm.[5]
Other uses
A combination of dextromethorphan and quinidine has been shown to alleviate symptoms of easy laughing and crying (pseudobulbar affect) in patients with amyotrophic lateral sclerosis and multiple sclerosis.[6] This drug is marketed as Nuedexta in the United States.
Intravenous quinidine is also indicated for treatment of Plasmodium falciparum malaria.[7] However, quinidine is not considered the first-line therapy for P. falciparum. The recommended treatments for P. falciparum malaria, according to the Toronto Notes 2008, are a combination of either quinine and doxycycline or atovaquone and proguanil (Malarone).
Quinidine sulfate is used in the treatment of atrial fibrillation in horses.
Quinidine-based ligands are used in AD-mix-β for Sharpless asymmetric dihydroxylation.
Veterinary Usage
The drug is also effective for the treatment of atrial fibrillation in horses. [8][9]
See also
- Antiarrhythmic agents
- Cardiac action potential
References
- ^ a b Hollman, A (1991). "Plants in Cardiology: Quinine and Quinidine". British heart journal. 66 (4): 301. PMC 1024726 . PMID 1747282. doi:10.1136/hrt.66.4.301.
- ^ Bowman, IA (1987). "Jean-Baptiste Senac and His Treatise on the Heart". Texas Heart Institute journal / from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital. 14 (1): 5–11. PMC 324686 . PMID 15227324.
- ^ Sneader, Walter (Jun 20, 2005). Drug Discovery: A History. John Wiley and Sons. p. 95. ISBN 978-0-471-89980-8.
- ^ Sadeque AJ, Wandel C, He H, Shah S, Wood AJ (2000). "Increased drug delivery to the brain by P-glycoprotein inhibition". Clin. Pharmacol. Ther. 68 (3): 231–7. PMID 11014404. doi:10.1067/mcp.2000.109156.
- ^ Rapid Interpretation of EKG's 6th Ed., Dubin
- ^ Brooks, BR; Thisted, RA; Appel, SH; Bradley, WG; Olney, RK; Berg, JE; Pope, LE; Smith, RA; AVP-923 ALS Study Group (2004). "Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial". Neurology. 63 (8): 1364–70. PMID 15505150. doi:10.1212/01.wnl.0000142042.50528.2f.
- ^ "From the Centers for Disease Control and Prevention. Availability and use of parenteral quinidine gluconate for severe or complicated malaria". JAMA. 285 (6): 730. February 2001. PMID 11236771. doi:10.1001/jama.285.6.730.
- ^ KURAKANE, Eiji; AMADA, Akio (1982). "Pharmacokinetic Studies on Quinidine Sulfate Orally Administered in Horses". Bulletin of Equine Research Institute. 1982 (19): 59–68. doi:10.11535/jes1977.1982.59. Retrieved March 3, 2017.
- ^ HIRAGA, Atsushi; SUGANO, Shigeru (2015). "History of research in Japan on electrocardiography in the racehorse". Journal of Equine Science. 26 (1): 1–13. doi:10.1294/jes.26.1.
External links
- MedlinePlus
- Poisons Information Monograph
|
Antiarrhythmic agents (C01B)
|
| Channel blockers |
|
class I
(Na+ channel blockers)
|
|
class Ia (Phase 0→ and Phase 3→)
|
- Ajmaline
- Disopyramide
- Hydroquinidine
- Lorajmine
- Prajmaline
- Procainamide#
- Quinidine#
- Sparteine
|
|
class Ib (Phase 3←)
|
- IV (Lidocaine#)
- enteral (Aprindine
- Mexiletine
- Tocainide)
|
|
class Ic (Phase 0→)
|
- Encainide‡
- Ethacizine
- Flecainide
- Indecainide‡
- Lorcainide
- Moracizine‡
- Propafenone
|
|
|
class III
(Phase 3→, K+ channel blockers)
|
- Amiodarone
- Bretylium
- Bunaftine
- Celivarone†
- Dofetilide
- Dronedarone
- E-4031†
- Ibutilide
- Nifekalant
- Sotalol
- Tedisamil
- Vernakalant
|
|
class IV
(Phase 4→, Ca2+ channel blockers)
|
|
|
Receptor agonists
and antagonists |
|
class II
(Phase 4→, β blockers)
|
- Nadolol
- Pindolol
- Propranolol
- cardioselective (Acebutolol
- Atenolol
- Esmolol
- Metoprolol)
|
|
A1 agonist
|
- Adenosine
- Benzodiazepines
- Barbiturates
|
|
M2
|
- muscarinic antagonist: Atropine
- Disopyramide
- Quinidine
muscarinic agonist: Digoxin
|
|
α receptors
|
- Amiodarone
- Bretylium
- Quinidine
- Verapamil
|
|
| Ion transporters |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
|
Antiparasitics – antiprotozoal agents – Chromalveolate antiparasitics (P01)
|
Alveo-
late |
Apicom-
plexa |
Conoidasida/
(Coccidiostats) |
| Cryptosporidiosis |
- thiazolides (nitazoxanide)
|
| Isosporiasis |
- trimethoprim/sulfamethoxazole#
|
| Toxoplasmosis |
- pyrimethamine
- sulfadiazine
|
|
| Aconoidasida |
| Malaria |
Individual
agents |
Hemozoin
inhibitors |
| Aminoquinolines |
- (4-): amodiaquine#
- chloroquine#
- hydroxychloroquine#
- (8-): primaquine#
- pamaquine‡
- tafenoquine†
|
| 4-Methanolquinolines |
- mefloquine#
- quinine#
- quinidine
|
| Other |
|
|
| Antifolates |
| DHFR inhibitors |
- biguanides
- chlorproguanil
- proguanil#
|
| Sulfonamides |
|
| Co-formulation |
- sulfadoxine/pyrimethamine (SP)#
|
|
Sesquiterpene
lactones |
- artemether#
- artemisinin
- artemotil
- artesunate#
- dihydroartemisinin
|
| Other |
- atovaquone (+ proguanil)
- tetracycline
- doxycycline#
- clindamycin
- mepacrine
- pyronaridine
- piperaquine
|
|
Combi-
nations |
| Fixed-dose (co-formulated) ACTs |
- artemether/lumefantrine#
- arterolane/piperaquine
- artesunate/amodiaquine (ASAQ)
- artesunate/mefloquine (ASMQ)
- artesunate/pyronaridine
- dihydroartemisinin/piperaquine
|
Other combinations
(not co-formulated) |
- artesunate/mefloquine
- artesunate/SP
- quinine/clindamycin
- quinine/doxycycline
- quinine/tetracycline
|
|
|
| Babesiosis |
|
|
|
Cilio-
phora |
- Balantidiasis: tetracycline
|
|
Hetero-
kont |
- Blastocystosis: metronidazole
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
